HER2阳性乳腺癌初始治疗选择
Choosing the Initial Treatment Approach in HER2-Positive Breast Cancer
在HER2阳性乳腺癌治疗中,医生需考虑手术与新辅助治疗的选择。对于肿瘤小于2cm且无淋巴结转移的患者,通常首选手术。在肿瘤介于1cm至2cm且无淋巴结转移的灰区患者中,医生会综合评估治疗效果、毒性反应和患者偏好,选择最佳治疗方案。新辅助治疗的疗效,特别是病理完全缓解率,是评估治疗效果的重要指标。
— "Beyond Diagnosis" continues with Megan Kruse on the myriad of factors that go into that decision
November 5, 2026 • 12 min read

Developed in partnership with the Our Partner
In "Beyond Diagnosis: Early HER2-Positive Breast Cancer," Cleveland Clinic breast oncologist Megan Kruse, MD, and host John Mangels discuss how clinicians can navigate increasingly complex treatment decisions while helping patients understand their diagnosis and care.
Each installment of this series explores key aspects of early HER2-positive breast cancer care, including interpreting pathology, navigating evolving therapies, individualizing treatment, and supporting patients through shared decision-making.
In this second episode, Kruse discusses choosing between upfront surgery and neoadjuvant therapy, balancing treatment efficacy with toxicity, and tailoring treatment decisions to patients' preferences and individual circumstances.
The following is a transcript of their remarks:
Mangels: Welcome to "Beyond Diagnosis," where we talk with doctors about treatment decisions and communicating with patients. I'm your host, John Mangels. HER2-positive breast cancer is a particularly aggressive disease. Targeted therapies are improving patient treatment options, but those advances have also made care more complex.
Today, we'll explore how breast oncologists make clinical decisions, adapt treatment as new information emerges, and help patients understand their choices. Our guest is Dr. Megan Kruse. Dr. Kruse is director of breast medical oncology and co-leader of the breast cancer program at Cleveland Clinic. Dr. Kruse, thanks so much for being here.
Kruse: Thanks for having me. I'm excited about this conversation today.
Mangels: In early-stage disease, a major choice is whether treatment should begin with surgery or systemic therapy. For a patient with newly diagnosed nonmetastatic HER2-positive cancer, what features would make you lean towards surgery?
Kruse: Yeah, this is also a big topic of conversation when we first meet a patient, because I think without the HER2 knowledge, many of them come in assuming they're just going to go to surgery first because that's what happens for the vast majority of patients with breast cancer, early-stage breast cancer. So I try to explain to them that when HER2 is positive, it gives us the opportunity to give treatments before surgery to help understand how effective those treatments are.
So usually in our guidelines, we use about a 2-cm tumor as a cutoff for how large a cancer in the breast has to be to consider that preoperative chemotherapy. And any lymph node positivity generally also moves a patient into that group where we would use systemic therapy before surgery or neoadjuvant therapy, whereas the smaller tumors and negative lymph nodes, typically we would think about going to surgery first. And the reason for that really is that the intensity of the systemic therapy that we give is vastly different if you do it before surgery versus after surgery.
Mangels: What about if there is a bit of a gray area in terms of which way to go?
Kruse: Yeah, so those are our T1cN0 patients more commonly. These are tumors that are bigger than a centimeter, but less than 2 cm and node negative clinically. Those are our most challenging situations because we want to be able to personalize and adapt the systemic therapy as much as possible. And the best way to do that is to give neoadjuvant therapy, but you worry that you're being too heavy handed if you're giving these neoadjuvant regimens to patients with those smaller tumors.
And so many times I will lay that out with a patient and say, "Hey, there is some gray zone here. Here's the pluses, here's the minuses. Here's what duration of treatment would look like." Some patients really can't imagine going through 4 to 6 months of treatment with a tumor still in their body. And if that's the case and we know that we're going to make their quality of life much worse by trying to do this, maybe that pushes us one way.
These are also the great cases for tumor board again, where you say, "Hey," to your breast surgeon, "How easy do you think the surgery's going to be in the current state? Do you need me to try to shrink this tumor? Does that lymph node really look negative?" So in the gray zone cases, again, you're putting the puzzle pieces together to figure out what's the best way forward. And at the end of the day, sometimes you just have to say, "This is what my gut tells me and we're going to go with it." And most patients actually really appreciate that and they'll say, "Whatever you think is best, we should just do it."
Mangels: When neoadjuvant therapy is indicated, you as a clinician have multiple anti-HER2 agents as options. How do you weigh things like efficacy, maturity of evidence, toxicity, and patient preferences when you're making your choice?
Kruse: Yeah. It's amazing that all of those factors are going through your head at one moment in time.
Mangels: Quite a juggling act.
Kruse: It's quite a juggling act. I would say that I come into a patient's room trying to have thought about all of this already so that I at least have my own mature sense of what I would recommend. Sometimes I go into that room and I learn about the patient and I realize I've got to flex. This plan is not going to work.
But I think when I'm coming up with that optimal plan, the first part of that is weighing largely efficacy and toxicity. When we think about these preoperative regimens in particular, the efficacy in terms of getting rid of all the cancer that you can see at the time of surgery really is our north star -- that's that pathologic complete response data point that we see in a lot of our trials. And the reason that that's so important is that pathologic complete response is an excellent surrogate for overall cancer control, overall survival, living without breast cancer recurrence.
And so when I'm looking at trials, that pathologic complete response data point is really what I'm going for because many of these trials will not have that mature survival data quite yet. But that doesn't mean I wouldn't act on that data. I'm comfortable enough with pCR (pathologic complete response) as an endpoint that we move on that.
But every improvement we've seen in pCR tends to come with some change in the side effect profile. And so that's where you have to think about which side effects are you willing to expose a certain patient to? Can they handle those? Are there long-term effects? And this is where I might view the decisions differently in a younger patient versus an older patient. Am I going to change their day-to-day functioning based on the side effects they develop? And in some of those younger patients, are there long-term consequences that if I cure them of the breast cancer, I may have to deal with a major complication 10, 15 years down the road?
So it really is a balancing act. And especially when it comes to those really long-term complications of treatment, you have to bring those up with your patients early on so that they're fully informed and that they know because some patients wouldn't be willing to take that risk. Even if it's 20% better for their cancer, they may say, "I'm not willing to worry about my heart later on." And we adapt to that.
Mangels: I'm guessing some of your patients are like, "I just want to get this tumor out of me." How do you approach and communicate with those patients that really just want to be done with the cutting part, the tumor excision part?
Kruse: Yeah. If those patients are in the gray zone based on their clinical staging, I would say we respect that decision and we may go to surgery right away. And it may change what their postsurgical systemic therapy looks like, but we still have great options. So if that is really a priority for patients, we honor that.
If there's a patient that has a larger tumor, has positive lymph nodes where I really think that neoadjuvant therapy will be important to them, I try to be as clear as possible as to why we're recommending it. And I think patients will often not realize that as we're treating with the systemic therapy that we are expecting the tumor to shrink and potentially go away. A lot of them worry that we're just getting the treatment in because we want to clear out the blood. It's really interesting that the perceptions of what chemotherapy and HER2-targeted therapy do can be all over the place when patients first come to our office.
But as you talk through that you may see this tumor shrink in real time, you may see your breasts go back to normal if it's heavier or firmer when you start treatment. And when that does happen and patients see that working, there's nothing better. They really believe in the treatment. And so being clear about what the goals are can really help with that conversation.
Mangels: It's also a learning opportunity for you as a clinician. You're seeing how that tumor responds to treatment, which is going to inform what you do going forward.
Kruse: Yeah, that's what it's all about actually. It's like an in-real-time experiment, of course an experiment that we have really excellent reasons to do. I largely tell patients that I want to know how well this treatment works on the tumor, and the only time I'm able to do that is if we still have the tumor in the breast or in the lymph nodes where we can physically feel it or see it on imaging.
Once it's cut out, we're relying on these drugs to work, but we don't really have a direct way to measure how well they're working. And actually that really resonates with patients because a lot of them want to know, did the treatment work or not? And then the counterpoint to that is if the treatment doesn't work, as disappointed as that makes all of us, it gives us an opportunity to flex after surgery and say, OK, we can use something different and try to clean up whatever may not have been killed off by the first wave of therapy.
Mangels: At the lower-risk end in patients, for example, with small node-negative tumors, how do you decide how much chemotherapy and HER2-directed therapy is adequate?
Kruse: It's a really interesting time because we're both deescalating for these low-risk patients and escalating for the higher-risk patients all at the same time. And so we're getting newer trials for these low-risk patients on a very frequent basis actually, where we're trying to remove the chemotherapy, where we're trying to lessen the number of doses of chemotherapy we're giving if we really still believe that we have to give it.
And there also are some approaches that we're using different imaging techniques to try to get a sense of really early response and escalating treatment if we're not seeing that early sign of response and then keeping the treatment lower intensity if we are seeing signs of response.
Mangels: So is that really the deciding factor for deescalation or not?
Kruse: Yeah, for the most part. If you have a lower-risk or medium-risk patient where you're still using preoperative therapy, you may see the early response as a sort of fork in the road of how intense you are with your treatment.
For those really low-risk patients where we've decided we're going to surgery first and then we're giving all of the systemic therapy after surgery, there we have a few different trial options where we can think about which particular type of chemotherapy may we want to use. Right now the conventional is HER2-targeted therapy with about 3 months of chemotherapy and then that HER2-targeted therapy continues on for the remainder of a year.
But there are some trials where we're looking at using different types of HER2-targeted therapy for various periods of time within that year to maybe have a more tolerable experience but still be really effective against the cancer.
Mangels: Are patients surprised to learn sometimes that chemotherapy doesn't have to be a part of the treatment plan?
Kruse: Absolutely, yes. And I think that...
Mangels: Surprised in a good way, I guess.
Kruse: Surprised in a good way, yeah. And we also have to do a lot of breaking down of what do these drugs actually do? What is chemotherapy? What is targeted therapy? Because many patients will assume that anything that goes in through the IV is chemo. And of course, some of our targeted therapies go through the IV, but they're not chemo and they have very different consequences for side effects, risk, how long the infusions are. And so that's a huge part of the education that we do upfront with patients.
Mangels: Chemotherapy is a familiar term with a lot of patients. Surgery, obviously people understand that, but we're talking about things like monoclonal antibodies, TKIs [tyrosine kinase inhibitors], antibody-drug conjugates. How do you explain those concepts in a way that is meaningful to patients? And do patients want to know the details of what those are or not?
Kruse: Yes, patients definitely want to know. Some are like, "OK, just give me what you think is best." But I would say most patients are wondering what the individual components of their treatment are.
Mangels: And what each does.
Kruse: And what they do and what that means for what they can expect, or if they run into complications, which one of these are really crucial, which ones might be able to be modified or dropped. And so I typically will start with going back to that idea of HER2 being our target and which of these drugs directly go against HER2, and then which of the drugs, like chemotherapy, might affect both HER2-positive cells and general cells of the body. And that's a pretty familiar concept, like what is more specific to the cancer and what might affect my whole body.
And then when it gets into the different types of HER2-targeted medicines, monoclonal antibodies versus TKIs, monoclonal antibodies are generally IV. TKIs are generally oral. So that's kind of a nice split to explain. I don't often get into where in the cells these drugs work.
Mangels: What the effect on the receptor is.
Kruse: Right. Right. Some patients will ask that, so I'm prepared to give that information if they want it, but most patients are satisfied by saying, "OK, this is my HER2-targeted drug."
Occasionally it comes up though where you might think about using monoclonal antibodies upfront, and then if you don't have a great response, you might bring around a TKI later. And there I do find telling patients like, "Hey, this is how it works differently. One of these drugs might be more successful getting to other parts of your body, like the brain, that others would not." And actually that does resonate with them, because then they see it as, "OK, this is a way that you're helping me take care of my whole body in different ways."
Mangels: You alluded to this earlier. How do your patients' lifestyles, support systems, socioeconomic status, how do those affect the treatment decisions that you make?
Kruse: Yeah, it's huge because the best treatment plan only works if the patient's actually able to receive it and able to receive it can be so many things. It can be getting the time off of work to be able to make it to the center, having a ride to get there, having the access to supportive medications like anti-nausea medications if copays are not too high.
So I'm very fortunate that I work within a team that has multiple different providers with different levels of expertise and we can each take our part in this. So my nurse may work on one aspect of what a patient's day-to-day life is like and filling in gaps where they may not have the support at home, but maybe we have resources. Our pharmacist helps in that way as well. And our social workers are really key team members for if we can support patients during this treatment journey with different resources.
Sometimes it's education, sometimes it's personnel support like home nursing. A lot of times it's logistics, like the rides to the center. But sometimes we really do have to adjust our plans to fit whatever a patient's individual circumstances...
Mangels: I was just going to ask you, are there cases where a patient's life situation just precludes doing what you initially thought you would be doing in terms of treatment?
Kruse: Absolutely. And in those situations, you try to be creative. You try to get them the best available medication that's going to be able to fit into that lifestyle. And again, it's different for everyone. And thankfully, as the advances in the field have happened, we have more and more options that allow us to create combinations. There's a ton of data in breast cancer where we can make sure that what we're thinking about doing in a creative way is also safe. That's a huge priority, but you do have to sometimes put your thinking cap on and say, "How might we approach this?"
And again, this is a space where I rely on colleagues, where I'll present cases at tumor board because sometimes you have your blinders on and you need that fresh perspective to say, "Have you considered doing it this way?" And that's very valuable because at the end of the day, we just want to do what's best for the patients.
Mangels: Thanks so much for your insights, Dr. Kruse. And thank you for joining us on "Beyond Diagnosis," where we explore not just what physicians know, but how to effectively and compassionately share that knowledge with patients. See you next time.
来源:MedPage Today · medpagetoday.com